
04/06/2025
Siiii, es Wegovy!!!
New findings from the SELECT trial, presented at , show semaglutide can offer early protection against heart attacks and strokes—even before significant weight loss or full dosing.
In adults with overweight or obesity and existing heart disease (but no diabetes), semaglutide reduced major cardiovascular events by around 40% within just 3–6 months.
This suggests benefits beyond weight loss, potentially through effects on inflammation, blood pressure, or blood vessels.
Another step forward in understanding the broader health impact of GLP-1 therapies.
https://www.eurekalert.org/news-releases/1083469